Literature DB >> 20933564

Development and evaluation of a formalin-inactivated West Nile Virus vaccine (WN-VAX) for a human vaccine candidate.

Guillermo Posadas-Herrera1, Shingo Inoue, Isao Fuke, Yuko Muraki, Cynthia A Mapua, Afjal Hossain Khan, Maria Del Carmen Parquet, Sadao Manabe, Osamu Tanishita, Toyokazu Ishikawa, Filipinas F Natividad, Yoshinobu Okuno, Futoshi Hasebe, Kouichi Morita.   

Abstract

A formalin-inactivated West Nile Virus (WNV) vaccine (WN-VAX) derived from the WNV-NY99 strain was tested for its safety, efficacy, dilution limit for complete protection, and cross-neutralization. Safety tests performed with experimental animals, bacteria, or cultured cell lines showed no evidence of short- or long-term adverse effects. WN-VAX also protected 100% of 4-week-old mice against a lethal challenge from the WNV-NY99 strain after two doses of intraperitoneal inoculation-even when the vaccine was diluted to 3.2ng/dose. Moreover, very limited cross-neutralization activity against Japanese encephalitis virus, Dengue virus, Murray Valley encephalitis virus, Yellow fever virus or St. Louis encephalitis virus was observed. Therefore, the WN-VAX satisfies the requirements for human trials planned to be done in Japan.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20933564     DOI： 10.1016/j.vaccine.2010.09.076

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  9 in total

1.  West nile virus.

Authors:  Georg Pauli; Ursula Bauerfeind; Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen
Journal:  Transfus Med Hemother       Date:  2013-07-04       Impact factor: 3.747

2.  An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody.

Authors:  Nikolai Petrovsky; Maximilian Larena; Venkatraman Siddharthan; Natalie A Prow; Roy A Hall; Mario Lobigs; John Morrey
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

3.  TLR3- and MyD88-dependent signaling differentially influences the development of West Nile virus-specific B cell responses in mice following immunization with RepliVAX WN, a single-cycle flavivirus vaccine candidate.

Authors:  Jingya Xia; Evandro R Winkelmann; Summer R Gorder; Peter W Mason; Gregg N Milligan
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

4.  The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys.

Authors:  Yuko Muraki; Takeshi Fujita; Masaaki Matsuura; Isao Fuke; Sadao Manabe; Toyokazu Ishikawa; Yoshinobu Okuno; Kouichi Morita
Journal:  Virol J       Date:  2015-04-09       Impact factor: 4.099

Review 5.  Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.

Authors:  Alex D Byas; Gregory D Ebel
Journal:  Pathogens       Date:  2020-01-07

6.  Comparison of β-Propiolactone and Formalin Inactivation on Antigenicity and Immune Response of West Nile Virus.

Authors:  Pritom Chowdhury; Rashmee Topno; Siraj A Khan; Jagadish Mahanta
Journal:  Adv Virol       Date:  2015-08-27

7.  Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults.

Authors:  Yuka Saito; Meng Ling Moi; Nozomi Takeshita; Chang-Kweng Lim; Hajime Shiba; Kuniaki Hosono; Masayuki Saijo; Ichiro Kurane; Tomohiko Takasaki
Journal:  BMC Infect Dis       Date:  2016-10-18       Impact factor: 3.090

Review 8.  The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.

Authors:  Lea Skak Filtenborg Frederiksen; Yibang Zhang; Camilla Foged; Aneesh Thakur
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

9.  An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults.

Authors:  Christopher W Woods; Ana M Sanchez; Geeta K Swamy; Micah T McClain; Lynn Harrington; Debra Freeman; Elizabeth A Poore; Dawn K Slifka; Danae E Poer DeRaad; Ian J Amanna; Mark K Slifka; Shu Cai; Venus Shahamatdar; Michael R Wierzbicki; Cyrille Amegashie; Emmanuel B Walter
Journal:  Vaccine       Date:  2019-01-18       Impact factor: 3.641
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.